Skip to main content
HeartCited

Potassium için Cardiac Arrhythmia

C Kanıt Küçük çalışmalardan sınırlı kanıt mevcuttur, ancak bazı olumlu sinyaller bulunmaktadır.

Hypokalemia is a well-established arrhythmia trigger. Guidelines support maintaining serum K+ >4.0 mEq/L. Research on supplementation benefit in normokalemic patients is unclear.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'heartcited.com'; const params = 'ingredient\u003Dpotassium\u0026condition\u003Darrhythmia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    


    
    

      Widget powered by
      .
      Free, no account required.
    

  




    








    

        

            C

        

        

            
Sonuç

            
            
Hypokalemia is a well-established arrhythmia trigger. Guidelines support maintaining serum K+ >4.0 mEq/L. Research on supplementation benefit in normokalemic patients is unclear.

            
            
        

    










    

  
Key Study Findings





    

        
        

            

                
                    Other
                
                
                n=19
                
                
                1 weeks
                
                
            

            
                Effect of moderate potassium-elevating treatment in long QT syndrome: the TriQarr Potassium Study.
            
            

                
                Dose: 50 mg
                
                
                vs: baseline
                
                
                Outcome: cardiac repolarisation
                
                
                Etki: None
                
                
                p=0.07
                
            

            
            
Popülasyon: lqts with a disease-causing kcnq1 or kcnh2 variant

            
        

        
        

            

                
                    Cohort Study
                
                
                n=157766
                
                
                26.0 weeks
                
                
            

            
                Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a …
            
            

                
                Dose: None
                
                
                vs: None
                
                
                Outcome: Incidence of hyperkalemia, mortality
                
                
                Etki: None
                
                
                None
                
            

            
            
Popülasyon: Newly diagnosed CKD patients in Denmark

            
        

        
        

            

                
                    Observational Study
                
                
                n=40
                
                
                
            

            
                Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1).
            
            

                
                Dose: anti-digoxin antibodies (Fab)
                
                
                vs: pre-treatment
                
                
                Outcome: serum digoxin and clinical outcomes
                
                
                Etki: Fab bound digoxin; no improved clinical outcomes
                
                
                None
                
            

            
            
Popülasyon: Chronic digoxin toxicity patients

            
        

        
        

            

                
                    Other
                
                
                
                
            

            
                Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, …
            
            

                
                Dose: None
                
                
                vs: None
                
                
                Outcome: None
                
                
                Etki: None
                
                
                None
                
            

            
            
Popülasyon: None

            
        

        
        

            

                
                    Other
                
                
                
                
            

            
                Potassium supplements or potassium-sparing agents.
            
            

                
                Dose: None
                
                
                vs: None
                
                
                Outcome: mineral status
                
                
                Etki: None
                
                
                None
                
            

            
            
Popülasyon: hypertensive patients

            
        

        
    







    
    

        
        

            

  
Key Statistics





            


    

        
5

        
Çalışmalar

    

    

        
300

        
Katılımcılar

    

    

        
            
            ↑
            
        
        
Positive

    

    

        C

        
Derece

    




        


        
        
        

            

  
Referenced Papers





            

                
                

                    

                        
                            Effect of moderate potassium-elevating treatment in long QT syndrome: the TriQarr Potassium Study.
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Open heart
                        2021
                        
                        6 atıf
                        
                    

                

                
                

                    

                        
                            Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study.
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Nephrology, dialysis, transplantation …
                        2018
                        
                        83 atıf
                        
                    

                

                
                

                    

                        
                            Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1).
                        
                        
                            
                                Observational
                            
                            
                            
                        
                    

                    

                        Clinical toxicology (Philadelphia, …
                        2016
                        
                        25 atıf
                        
                    

                

                
                

                    

                        
                            Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common …
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Therapeutic drug monitoring
                        2011
                        
                        17 atıf
                        
                    

                

                
                

                    

                        
                            Potassium supplements or potassium-sparing agents.
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Acta pharmacologica et …
                        1984
                        
                        3 atıf
                        
                    

                

                
            

        

        

        
        
        

            

  
Dosage & Usage





            
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units


            
            

                
Yaygın Kullanılan Dozajlar

                

                    
                    

                        
supplements:

                        
Typically 99 mg/dose (FDA limit per unit)

                    

                    
                    

                        
dashdiettarget:

                        
4,700 mg/day

                    

                    
                    

                        
whorecommendation:

                        
3,510 mg/day from food

                    

                    
                

                
                

                    Üst sınır: No UL for dietary potassium in healthy individuals; supplemental potassium should be supervised
                

                
            

            

            
            

                
Araştırmalarda İncelenen Dozajlar

                

                    

                        
                            

                                Dozaj
                                Süre
                                Etki
                                N
                            

                        
                        
                            
                            

                                50 mg
                                1 weeks
                                
                                    
                                    Neutral
                                    
                                
                                19
                            

                            
                            

                                None
                                26.0 weeks
                                
                                    
                                    Mixed
                                    
                                
                                157766
                            

                            
                            

                                anti-digoxin antibodies (Fab)
                                --
                                
                                    
                                    Neutral
                                    
                                
                                40
                            

                            
                            

                                None
                                --
                                
                                    
                                    Positive
                                    
                                
                                --
                            

                            
                            

                                None
                                --
                                
                                    
                                    Mixed
                                    
                                
                                --
                            

                            
                        
                    

                

            

            

            
            

                En iyi alım zamanı: With meals to reduce GI irritation; divide supplemental doses throughout the day
            

            
        

        

        
        
        

            

  
Safety & Side Effects





            

                
                

                    
Bildirilen Yan Etkiler

                    
    
                        
                        
  • 
                            ⚠
                            Gastrointestinal irritation (nausea, vomiting, diarrhea)
                        
    • 
                        
                        
  • 
                            ⚠
                            Hyperkalemia risk in patients with renal impairment
                        
    • 
                        
                        
  • 
                            ⚠
                            Cardiac arrhythmias at excessively high serum levels
                        
    • 
                        
                    

                

                

                
                

                    
Bilinen Etkileşimler

                    
    
                        
                        
  • 
                            ●
                            ACE inhibitors (increased hyperkalemia risk)
                        
    • 
                        
                        
  • 
                            ●
                            ARBs (increased hyperkalemia risk)
                        
    • 
                        
                        
  • 
                            ●
                            Potassium-sparing diuretics (increased hyperkalemia risk)
                        
    • 
                        
                        
  • 
                            ●
                            NSAIDs (may increase potassium retention)
                        
    • 
                        
                    

                

                

                
                

                    

                        Tolere edilebilir üst alım: No UL for dietary potassium in healthy individuals; supplemental potassium should be supervised
                    

                

                
            

            

                Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.
            

        

        

        
        
        

            

  
Frequently Asked Questions





            




    
    

        
            Does Potassium help with Cardiac Arrhythmia?
            
        
        

            Based on 5 studies with 300 participants, there is limited but promising evidence that Potassium may support Cardiac Arrhythmia management. Our evidence grade is C (Some Evidence).
        

    

    
    

        
            How much Potassium should I take for Cardiac Arrhythmia?
            
        
        

            Studies have used various dosages. A commonly studied range is Typically 99 mg/dose (FDA limit per unit). Always consult your healthcare provider before starting any supplement regimen.
        

    

    
    

        
            Are there side effects of Potassium?
            
        
        

            Reported side effects may include Gastrointestinal irritation (nausea, vomiting, diarrhea), Hyperkalemia risk in patients with renal impairment, Cardiac arrhythmias at excessively high serum levels. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
        

    

    
    

        
            How strong is the evidence for Potassium and Cardiac Arrhythmia?
            
        
        

            We rate the evidence as Grade C (Some Evidence). This rating is based on 5 peer-reviewed studies with 300 total participants. The overall direction of effect is positive.
        

    

    




        

        

        
        
        

            

  




            

                
                

                    
Şu durum için diğer içerikler: Cardiac Arrhythmia

                    

                        
                        
                            Omega-3 Fatty Acids (EPA/DHA)
                            B

                        
                        
                        
                            Magnesium
                            B

                        
                        
                        
                            Coenzyme Q10 (CoQ10)
                            C

                        
                        
                    

                

                

                
                

                    
Potassium diğer sağlık durumları için

                    

                        
                        
                            High Blood Pressure (Hypertension)
                            B

                        
                        
                    

                

                
            

        

        

    


    
    






  
References

  
    
    
    
  1. 
      [1]
      Peter Marstrand et al..
      Open Heart.
      2021.
      Effect of moderate potassium-elevating treatment in long QT syndrome: the TriQarr Potassium Study.
      doi:10.1136/openhrt-2021-001670
      PubMed
    
    2. 
    
    
  2. 
      [2]
      Reimar W Thomsen et al..
      Nephrol Dial Transplant.
      2018.
      Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study.
      doi:10.1093/ndt/gfx312
      PubMed
    
    3. 
    
    
  3. 
      [3]
      Betty S Chan et al..
      Clin Toxicol (Phila).
      2016.
      Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1).
      doi:10.1080/15563650.2016.1175620
      PubMed
    
    4. 
    
    
  4. 
      [4]
      Andrea DeFrance et al..
      Ther Drug Monit.
      2011.
      Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common …
      doi:10.1097/FTD.0b013e3181fd4c30
      PubMed
    
    5. 
    
    
  5. 
      [5]
      S Persson.
      Acta Pharmacol Toxicol (Copenh).
      1984.
      Potassium supplements or potassium-sparing agents.
      doi:10.1111/j.1600-0773.1984.tb03642.x
      PubMed
    
    6. 
    
  















    

        FDA Sorumluluk Reddi:
        Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.